Md Saiful Islam Khan/iStock by way of Getty Pictures
Shares of Ventyx (NASDAQ:VTYX) plunged 20% in after-hours buying and selling after the biotech firm launched outcomes from a Part 2 clinal trial for its drug VTX002 within the remedy of moderate-to-severe lively ulcerative colitis.
Calling the outcomes “constructive,” Ventyx mentioned the 60mg dose of VTX002 met the research’s major endpoint of scientific remission with a “excessive charge of full endoscopic remission.”
It added that 28% of sufferers on the 60mg dose and 24% of sufferers on the 30 mg dose achieved scientific remission at week 13 of the research, in contrast with 11% on placebo.
Ventyx additionally mentioned that 29% of sufferers on the 60mg dose and 21% on the 30mg dose achieved the research’s secondary endpoint of full endoscopic remission at week 13, in contrast with 7% on placebo.